Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Single-Dose, Randomized, Active and Placebo Controlled, Four-Period, Cross-Over Study of the Safety and Efficacy of Intranasal Epinephrine After Administration of ARS -1 or Albuterol in Subjects With Persistent Asthma

NCT05363670 is registered in ClinicalTrials.gov with ARS Pharmaceuticals, Inc. as lead sponsor.

NCT NCT05363670
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05363670 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Single-Dose, Randomized, Active and Placebo Controlled, Four-Period, Cross-Over Study of the Safety and Efficacy of Intranasal Epinephrine After Administration of ARS -1 or Albuterol in Subjects With Persistent Asthma
Lead sponsor
ARS Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Completed
Start date
July 28, 2022
Completion date
February 2, 2024
Enrollment
18 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

asthma